One each in India and South Africa
Suven Life Sciences has secured one product patent each from India and South Africa corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2028 and 2032 respectively.Powered by Capital Market - Live News
